|Summary sheet: DiPT|
|Routes of Administration|
N,N-Diisopropyltryptamine (also known as DiPT) is a lesser-known psychedelic substance of the tryptamine class that produces atypical psychedelic effects when administered. It is related in structure to psychedelic tryptamine compounds like 4-HO-DiPT, 5-MeO-DiPT, and MiPT.
The first human trials of DiPT were undertaken by in 1975 by Alexander Shulgin, who would co-author and publish a paper detailing its synthesis and human psychopharmacology in 1981. A summary of the synthesis and reports of human use is included in Shulgin's 1997 book TiHKAL ("Tryptamines I Have Known And Loved")
While the majority of psychedelics affect the visual sense, the effects of DiPT are noted for being primarily auditory in nature. It has been suggested that DiPT may have value to neurological research due to its complex audio distorting effects.
Very little data exists about the pharmacological properties, metabolism, and toxicity of DiPT, and it has a limited history of human use. It is sometimes sold as a research chemical by online vendors. It is highly advised to use harm reduction practices if using this substance.
DiPT, or N,N-diisopropyltryptamine, is a synthetic indole alkaloid molecule of the tryptamine class. Tryptamines share a core structure comprised of a bicylic indole heterocycle attached at R3 to an amino group via an ethyl side chain.
DiPT also contains two isopropyl groups bound to the terminal amine RN of its tryptamine backbone. Isopropyl groups are a three carbon (propyl) chain bound at the middle carbon to the chemical structure. DiPT has substituted analogues such 5-MeO-DiPT.
The psychedelic effects of DiPT are believed to come from its efficacy at the 5-HT2A receptor. However, the role of these interactions and how they result in the psychedelic experience remains subject to on-going scientific investigation.
Although DiPT's effects are primarily auditory, some users have reported lack of coordination or balance, stomach bloating, confusion, depersonalization and minor visual distortions at higher doses. Aside from these, the most prevalent non-auditory effect is inner ear pressure (which has been painful in some instances such as when combined with MDMA).
One experiment involving subjects with perfect pitch indicated that there is no clear relationship between perceived pitch and actual pitch.
Although recent unpublished research has examined the role of DiPT in hearing perception in rodents, it is not clear that the auditory effect is preserved in nonhuman species; this finding indicates that DiPT does not produce effects similar to other tryptamine psychedelics such as DPT and 5-MeO-DMT in acoustic startle reflex paradigms. DiPT still remains widely unexplored.
The effects listed below are based upon the subjective effects index and personal experiences of PsychonautWiki contributors. These effects should be taken with a grain of salt and will rarely (if ever) occur all at once, but heavier doses will increase the chances of inducing a full range of effects. Likewise, adverse effects become much more likely on higher doses and may include serious injury or death.
- There is much speculation as to the nature of DiPT's aural distortion. At lower dosages, it has been reported to have an effect similar to a flanging, or a phase shift. At medium and higher dosages, the effect of DiPT is typically a radical shift downward in perceived pitch. This shift tends to be nonlinear in that the shift downwards varies in relation to the initial pitch. This can produce bizarre sounds and render music disharmonious. These auditory effects of DiPT are common in their occurrence and exhibit a full range of effects which commonly includes:
There are currently no anecdotal reports which describe the effects of this compound within our experience index. Additional experience reports can be found here:
Toxicity and harm potential
The toxicity and long-term health effects of recreational DiPT do not seem to have been studied in any scientific context and the exact toxic dose is unknown. This is because DiPT is a research chemical with very little history of human usage.
Anecdotal reports from those who have tried DiPT suggests that there are no negative health effects attributed to simply trying the drug by itself at low to moderate doses and using it very sparingly (but nothing can be completely guaranteed). Independent research should always be done to ensure that a combination of two or more substances is safe before consumption.
It is strongly recommended that one use harm reduction practices when using this drug.
Tolerance and addiction potential
DiPT is not habit-forming and the desire to use it can actually decrease with use. It is most often self-regulating.
Tolerance to the effects of DiPT are built almost immediately after ingestion. After that, it takes about 3 days for the tolerance to be reduced to half and 7 days to be back at baseline (in the absence of further consumption). DiPT presents cross-tolerance with all psychedelics, meaning that after the consumption of DiPT all psychedelics will have a reduced effect.
This legality section is a stub.
As such, it may contain incomplete or wrong information. You can help by expanding it.
- Latvia: DiPT is a Schedule I drug.
- United Kingdom: DiPT is a Class A drug in the United Kingdom as a result of the tryptamine catch-all clause.
- United States: DiPT is unscheduled in the United States. It may be considered an analogue of DET, a Schedule I drug under the Controlled Substances Act. As such, the sale for human consumption or the use for illicit non-medical or industrial intents and purposes could be prosecuted as crimes under the Federal Analogue Act.
- Florida: DiPT is a Schedule I controlled substance in the state of Florida making it illegal to buy, sell, or possess.
- New Zealand: DiPT is an analogue of DMT, so is a Class C controlled drug in New Zealand.
- Germany: DiPT is not controlled in Germany. There is a draft by the Federal Ministry of Health, adding it to the NpSG, that will enter into force when the regulation is promulgated.
- Shulgin, Alexander. "Pharmacology Lab Notes #1". Lafayette, CA. (1960-1976). p177 (Erowid.org) | https://erowid.org/library/books_online/shulgin_labbooks/shulgin_labbook1_searchable.pdf
- Shulgin, AT; Carter, MF. N,N-diisopropyltryptamine (DIPT) and 5-methoxy-N,N-diisopropyltryptamine (5-MeO-DIPT). Two orally active tryptamine analogs with CNS activity. Commun. Psychopharmacol., 1 Jan 1981, 4 (5), 363–369 | https://www.ncbi.nlm.nih.gov/pubmed/6949674
- Shulgin, Alexander (1997). TiHKAL: Tryptamines I Have Known and Loved. Berkeley, CA USA: Transform Press. pp. 403–406. ISBN 0-9630096-9-9.
- Noteikumi par Latvijā kontrolējamajām narkotiskajām vielām, psihotropajām vielām un prekursoriem (Triptamīni) | http://likumi.lv/doc.php?id=121086
- Misuse of Drugs Act 1971 (Legislation.gov.uk) |http://www.legislation.gov.uk/ukpga/1971/38/schedule/2/part/I#reference-M_F_c7632653-ddad-4420-f307-e3da1e36d30e
- The 2015 Florida Statutes | http://leg.state.fl.us/statutes/index.cfm?App_mode=Display_Statute&URL=0800-0899/0893/0893.html